Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 10 |
| Pathophysiology and Etiology | 9 | 2 |
| Epidemiology | 11 | 2 |
| Disease Progression | 13 | 2 |
| Treatment | 15 | 4 |
| Marketed Products | 19 | 14 |
| Hormonal Therapies | 19 | 1 |
| Zoladex (Goserelin) AstraZeneca | 19 | 2 |
| Lupron Depot (Leuprolide acetate) Abbvie | 21 | 1 |
| Triptorelin | 22 | 1 |
| Firmagon (degarelix) Ferring | 22 | 1 |
| Casodex (Bicalutamide) | 23 | 1 |
| Summary | 23 | 1 |
| Chemotherapy agents | 24 | 1 |
| Taxotere (Docetaxel) Sanofi | 24 | 1 |
| Jevtana (Cabazitaxel) Sanofi | 25 | 1 |
| Therapeutic Vaccines | 26 | 1 |
| Provenge (sipuleucel-T) Dendreon | 26 | 1 |
| Targeted therapies (Second Generation Anti-androgens) | 27 | 1 |
| Zytiga (Abiraterone acetate) Janssen | 27 | 1 |
| Xtandi (Enzalutamide) Astellas/Medivation | 27 | 1 |
| Bone Metastasis Treatments | 28 | 1 |
| Xofigo (Radium 223) Bayer/Algeta | 28 | 1 |
| Xgeva (denosumab) Amgen | 29 | 1 |
| Zometa (zoledronic acid) Novartis | 29 | 1 |
| Heat Map for Marketed Products | 30 | 3 |
| Prostate Cancer Developmental Pipeline | 33 | 14 |
| Overall Pipeline | 33 | 2 |
| Mechanisms of Action | 35 | 1 |
| Clinical Trials | 36 | 1 |
| Attrition Rate | 36 | 2 |
| Enrollment | 38 | 3 |
| Duration | 41 | 2 |
| Key Late-Stage Pipeline Molecules | 43 | 1 |
| Cometriq (Cabozantinib) Exelixis | 43 | 1 |
| OGX-011 (custirsen sodium) Teva | 43 | 1 |
| TAK-700 (orteronel) Takeda | 44 | 1 |
| ProstAtak (AdvTk+ valcyclovir) Advantagene | 44 | 1 |
| ProstVac Bavarian Nordic | 44 | 1 |
| Tasquinimod Active Biotech | 45 | 1 |
| Yervoy (Ipilimumab) Bristol-Myers Squibb | 46 | 1 |
| ARN-509 Aragon Pharmaceuticals, Johnson and Jonhson | 46 | 1 |
| Market Forecast to 2019 | 47 | 13 |
| Global | 47 | 1 |
| Treatment Usage Patterns | 47 | 2 |
| Market Size | 49 | 1 |
| North America | 50 | 1 |
| US | 50 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Market Size | 51 | 1 |
| Canada | 52 | 1 |
| Treatment Usage Patterns | 52 | 1 |
| Market Size | 53 | 1 |
| Five European Markets | 54 | 1 |
| Treatment Usage Patterns | 54 | 2 |
| Annual Cost of Therapy | 56 | 1 |
| Market Size | 57 | 1 |
| Japan | 58 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Market Size | 59 | 1 |
| Prostate Cancer Therapeutics: Drivers and Barriers | 60 | 2 |
| Drivers | 60 | 1 |
| Major Unmet Treatment Needs of Late Stage Prostate Cancer Patients | 60 | 1 |
| Increasing Disease Population | 60 | 1 |
| New Drugs Entering the Market | 60 | 1 |
| Rapid and Robust Uptake of Recently Approved High-Cost Therapies | 60 | 1 |
| Rapid Inflation Rate for Specialty Pharmaceutical Products in the US | 60 | 1 |
| Market Capture of Previously Untreated Patient Segments | 61 | 1 |
| Barriers | 61 | 1 |
| Uncertain Treatment Algorithm | 61 | 1 |
| Uptake Limited by High Prices for New Products | 61 | 1 |
| Patent Expiry of Taxotere | 61 | 1 |
| Intensifying Competition Acting as a Barrier to Market Capture | 61 | 1 |
| Licensing and Co-development Deals Analysis | 62 | 8 |
| Licensing Deals | 62 | 3 |
| Algeta Enters into Licensing Agreement with Bayer Schering for Xofigo | 65 | 1 |
| Sanofi-Aventis Enters into a Licensing Agreement with Oxford BioMedica | 65 | 1 |
| Novacea Enters Into Licensing Agreement With Schering-Plough For Asentar | 65 | 1 |
| Teva Pharma Enters into a Licensing Agreement with Oncogenex Pharma for OGX-011 | 65 | 1 |
| Hoffman La Roche Enters into a Licensing Agreement with Inovio Pharmaceuticals for Prostate Cancer and Hepatitis B Immunotherapy Products | 66 | 1 |
| Colby Pharmaceutical Company Enters into a Licensing Agreement with MannKind for Cancer Immunotherapy Products | 66 | 1 |
| Ipsen Enters into a Licensing Agreement with GTx | 66 | 1 |
| Protox Therapeutics Enters into a Licensing Agreement with Kissei Pharma | 67 | 1 |
| AEterna Zentaris Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix | 67 | 1 |
| Orion Corporation Enters Into Agreement With Indevus Pharmaceuticals | 67 | 1 |
| Co-Development Deals | 68 | 1 |
| Medivation Enters into Co-Development Agreement with Astellas Pharma | 69 | 1 |
| Takeda Pharma Enters into an Agreement with Cell Genesys | 69 | 1 |
| Active Biotech Enters into Co-Development Agreement with Ipsen | 69 | 1 |
| Appendix | 70 | 38 |
| Market Definitions | 70 | 1 |
| Abbreviations | 70 | 3 |
| Sources | 73 | 5 |
| Sources for Marketed Products Heat Map | 78 | 1 |
| Scientific Support | 78 | 1 |
| Research Methodology | 78 | 5 |
| Coverage | 79 | 1 |
| Secondary Research | 79 | 1 |
| Therapeutic Landscape | 79 | 1 |
| Epidemiology-Based Forecasting | 80 | 1 |
| Market Size by Geography | 81 | 1 |
| Geographical Landscape | 82 | 1 |
| Pipeline Analysis | 82 | 1 |
| Competitive Landscape | 82 | 1 |
| Expert Panel Validation | 82 | 1 |
| All Publicly Announced Pipeline Products, by Phase | 83 | 21 |
| Discovery | 83 | 2 |
| Preclinical/IND-Filed | 85 | 9 |
| Phase I | 94 | 3 |
| Phase II | 97 | 4 |
| Phase III/Pre-Registration | 101 | 2 |
| Undisclosed Stage of Development | 103 | 1 |
| Tabular Forecast Data | 103 | 5 |
| Global | 103 | 1 |
| US | 104 | 1 |
| UK | 104 | 1 |
| France | 105 | 1 |
| Germany | 105 | 1 |
| Italy | 106 | 1 |
| Spain | 106 | 1 |
| Japan | 107 | 1 |
| Canada | 107 | 1 |
| Disclaimer | 107 | 1 |